Compare AXIL & NEPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXIL | NEPH |
|---|---|---|
| Founded | 2015 | 1997 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 40.8M | 39.0M |
| IPO Year | 2017 | 2004 |
| Metric | AXIL | NEPH |
|---|---|---|
| Price | $5.70 | $3.51 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $6.25 |
| AVG Volume (30 Days) | 17.2K | ★ 38.4K |
| Earning Date | 10-06-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 230.00 | ★ 1000.00 |
| EPS | 0.05 | ★ 0.12 |
| Revenue | ★ $30,847,570.00 | $18,789,000.00 |
| Revenue This Year | $26.77 | $17.81 |
| Revenue Next Year | $17.73 | $15.90 |
| P/E Ratio | $109.60 | ★ $29.75 |
| Revenue Growth | 17.48 | ★ 32.67 |
| 52 Week Low | $4.28 | $2.66 |
| 52 Week High | $9.86 | $6.42 |
| Indicator | AXIL | NEPH |
|---|---|---|
| Relative Strength Index (RSI) | 45.23 | 44.10 |
| Support Level | $5.45 | $3.19 |
| Resistance Level | $6.47 | $3.78 |
| Average True Range (ATR) | 0.51 | 0.28 |
| MACD | 0.00 | 0.03 |
| Stochastic Oscillator | 42.19 | 69.23 |
AXIL Brands Inc is engaged in the manufacturing, marketing, sale, and distribution of high tech hearing and audio enhancement and protection products, professional quality hair and skin care products, and the delivery of marketing services. The company has three operating segments: hearing enhancement and protection, hair and skin care and marketing services. The company generates majority of revenue from Hearing enhancement and protection segment. Hearing Enhancement and Protection Products are In-ear protection devices, Over-ear protection devices, and Accessories and others.
Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets. In medical markets, it sells water filtration products and waterborne pathogen detection products. In commercial markets, the company manufactures and sells water filters that improve the taste and odor of water and reduce biofilm, bacteria, and scale build-up in downstream equipment. The company's subsidiary is engaged in the development of its second-generation hemodiafiltration system and other products focused on improving therapies for patients with renal disease. The company generates almost all of revenue from product sales and a small amount from royalty revenue and other revenues.